[go: up one dir, main page]

HN2003000193A - Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age. - Google Patents

Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age.

Info

Publication number
HN2003000193A
HN2003000193A HN2003000193A HN2003000193A HN2003000193A HN 2003000193 A HN2003000193 A HN 2003000193A HN 2003000193 A HN2003000193 A HN 2003000193A HN 2003000193 A HN2003000193 A HN 2003000193A HN 2003000193 A HN2003000193 A HN 2003000193A
Authority
HN
Honduras
Prior art keywords
diseases
nephropatia
treatment
age associated
vasopeptidase inhibitors
Prior art date
Application number
HN2003000193A
Other languages
English (en)
Inventor
Sanofi Aventis Deutschland Gmbh
Original Assignee
Sanofi Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland Gmbh filed Critical Sanofi Aventis Deutschland Gmbh
Publication of HN2003000193A publication Critical patent/HN2003000193A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) ES UNA PEPTIDIL DIPEPTIDASA QUE CATALIZA LA CONVERSION DE ANGIOTENSINA I EN ANGIOTENSINA II.
HN2003000193A 2002-06-28 2003-06-26 Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age. HN2003000193A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen

Publications (1)

Publication Number Publication Date
HN2003000193A true HN2003000193A (es) 2004-10-27

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000193A HN2003000193A (es) 2002-06-28 2003-06-26 Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age.

Country Status (38)

Country Link
US (2) US6930103B2 (es)
EP (1) EP1519732B1 (es)
JP (1) JP4564354B2 (es)
KR (1) KR101072235B1 (es)
CN (1) CN100366254C (es)
AR (1) AR040343A1 (es)
AT (1) ATE548040T1 (es)
AU (1) AU2003280440B2 (es)
BR (1) BR0312250A (es)
CA (1) CA2490277C (es)
CR (1) CR7667A (es)
CY (1) CY1112905T1 (es)
DE (1) DE10229180A1 (es)
DK (1) DK1519732T3 (es)
EC (1) ECSP045513A (es)
ES (1) ES2383889T3 (es)
HN (1) HN2003000193A (es)
HR (1) HRP20041212B1 (es)
IL (2) IL165935A0 (es)
MA (1) MA27281A1 (es)
MX (1) MXPA04012230A (es)
NO (1) NO334811B1 (es)
NZ (1) NZ537480A (es)
OA (1) OA12871A (es)
PA (1) PA8576501A1 (es)
PE (1) PE20040582A1 (es)
PL (1) PL218070B1 (es)
PT (1) PT1519732E (es)
RS (1) RS52478B (es)
RU (1) RU2336080C2 (es)
SI (1) SI1519732T1 (es)
SV (1) SV2004001560A (es)
TN (1) TNSN04262A1 (es)
TW (1) TWI326215B (es)
UA (1) UA82845C2 (es)
UY (1) UY27869A1 (es)
WO (1) WO2004002492A1 (es)
ZA (1) ZA200409382B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DK0589037T3 (da) * 1991-03-01 1996-09-16 Zeria Pharm Co Ltd Indanderivat og thromboxanantagonist indeholdende samme
RU2098411C1 (ru) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
CA2078758C (en) * 1991-09-27 2003-12-09 Alan M. Warshawsky 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
HU220596B1 (hu) * 1992-02-14 2002-03-28 Merrell Dow Pharmaceuticals Inc. 7-Szubsztituált pirido-benzazepin-karbonsav-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
CA2184696C (en) * 1994-03-24 2001-01-02 Gary A. Flynn Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives
JPH11508894A (ja) * 1995-06-30 1999-08-03 メルク エンド カンパニー インコーポレーテッド Ace阻害剤とaii拮抗薬を用いる腎疾患の治療方法
CA2241856C (en) 1995-12-27 2006-10-17 Yoshitomi Pharmaceutical Industries Ltd. Agent for prophylaxis and treatment of diabetic complications
MXPA02001694A (es) * 1999-08-30 2002-08-06 Aventis Pharma Gmbh Uso de inhibidores del sistema renina-angiotensina en la prevencion de eventos cardiovasculares.
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
JP4392167B2 (ja) * 2001-04-12 2009-12-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング メルカプトアセチルアミド誘導体、その製造方法およびその使用
WO2003013434A2 (en) * 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace

Also Published As

Publication number Publication date
BR0312250A (pt) 2005-04-26
PL218070B1 (pl) 2014-10-31
RS100704A (sr) 2007-02-05
HRP20041212B1 (hr) 2013-06-30
MXPA04012230A (es) 2005-02-25
RU2336080C2 (ru) 2008-10-20
CA2490277C (en) 2011-11-01
KR101072235B1 (ko) 2011-10-12
AU2003280440A1 (en) 2004-01-19
AU2003280440B2 (en) 2009-07-16
PA8576501A1 (es) 2004-02-07
UY27869A1 (es) 2003-12-31
PT1519732E (pt) 2012-05-22
ES2383889T3 (es) 2012-06-27
WO2004002492A1 (en) 2004-01-08
TNSN04262A1 (en) 2007-03-12
JP4564354B2 (ja) 2010-10-20
CN100366254C (zh) 2008-02-06
IL165935A0 (en) 2006-01-15
EP1519732A1 (en) 2005-04-06
PE20040582A1 (es) 2004-10-18
TWI326215B (en) 2010-06-21
MA27281A1 (fr) 2005-04-01
NO334811B1 (no) 2014-06-02
TW200406214A (en) 2004-05-01
OA12871A (en) 2006-09-15
US20040058911A1 (en) 2004-03-25
UA82845C2 (en) 2008-05-26
EP1519732B1 (en) 2012-03-07
DE10229180A1 (de) 2004-01-29
ECSP045513A (es) 2005-03-10
DK1519732T3 (da) 2012-06-18
IL165935A (en) 2010-12-30
HRP20041212A2 (en) 2005-06-30
NO20050425L (no) 2005-01-25
SI1519732T1 (sl) 2012-05-31
ZA200409382B (en) 2006-01-25
NZ537480A (en) 2005-11-25
CN1665512A (zh) 2005-09-07
KR20050013642A (ko) 2005-02-04
CA2490277A1 (en) 2004-01-08
RS52478B (sr) 2013-02-28
US6930103B2 (en) 2005-08-16
PL372992A1 (en) 2005-08-08
US20050171090A1 (en) 2005-08-04
RU2005102087A (ru) 2005-07-10
SV2004001560A (es) 2004-02-26
HK1079435A1 (zh) 2006-04-07
US7514423B2 (en) 2009-04-07
CY1112905T1 (el) 2016-04-13
JP2005533815A (ja) 2005-11-10
CR7667A (es) 2005-06-16
AR040343A1 (es) 2005-03-30
ATE548040T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
MY137757A (en) Therapeutic treatment
TW200612918A (en) Lonidamine analogs
HN2003000227A (es) Inhibidores de quinasas
UA94221C2 (en) Lipocalin protein
NO20020299D0 (no) Behandling og sammensetning for oppnåelse av antialdring av hud med Corneum Protease aktivering
EA201100506A1 (ru) Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
DE60115842D1 (de) Ventilanordnung
HN2003000247A (es) Combinaciones sinergicas
MXPA05006629A (es) Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador.
HN2003000208A (es) Estructura perfeccionada de suela impermeable y transpirante para calzados
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
BR0306820A (pt) Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus
EP1740183B8 (en) Novel use for pde5 inhibitors
EP1546182A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSING AND TREATING TUMORS
MXPA05003818A (es) Perfilamiento de la expresion genica de muestras ffpe.
PA8574201A1 (es) Nueva combinacion
HN2003000193A (es) Uso de inhibidores de vasopeptidasa en el tratamiento de enfermedades metabolicas, nefropatia y enfermedades asociadas con age.
MX2007002277A (es) Metodos para formar retinoides y usos de los mismos.
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
NO20071330L (no) Enzyminhibitor i leukemi
DE50309647D1 (de) Ng fibrotischer erkrankungen
SG148860A1 (en) Stereospecific reduction of sapogen-3-ones
MA30374B1 (fr) Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine